Recent findings might help ease concerns for women suffering with lupus and interested in having a child. New research concluded that most women diagnosed with lupus and whose disease is not very active can go through a safe pregnancy. The results were published in the Annals of Internal Medicine. It has been suggested that women with…
Susan Manzi, Chair of the Department of Medicine at Allegheny Health Network, was recently presented with the Lupus Foundation of America’s (LFA) National Advocacy Leadership Award. The LFA awarded those with exquisite and distinguished researched who lead and support biomedical innovation to accelerate the development of novel treatments for illnesses such as lupus.
Actelion recently announced its commitment to accelerate clinical development efforts concerning immunological disorders following a broad medical, scientific and commercial assessment of a series of its selective S1P1 receptor modulators, discovered in-house. The company believes that this effort will lead to new approaches addressing systemic lupus erythematosus. A second selective S1P1 receptor modulator will be…
Anthera Pharmaceuticals, Inc. announced the completion of its Phase 3 trial (CHABLIS-SC1), which evaluated the effect of blisibimod in patients suffering with systemic lupus erythematosus. The CHABLIS-SC1 study was evaluated by an independent statistician to assess the SRI-6 response 24 weeks after the beginning of the…
UBM Medica US, a company that delivers integrated and strategic communications solutions, recently announced that Rheumatology Network, an online network dedicated to rheumatologists, will feature a debate with experts on the barriers to investigation into new treatments for rheumatic diseases such as lupus. The topic is based on an article…
ImmuPharma PLC and Simbec-Orion Group Limited recently announced a collaboration agreement for the execution of a Pivotal Phase III clinical study of ImmuPharma’s Lupuzorâ„¢, the company’s lead compound to treat Systemic Lupus Erythematosus, a chronic and life-threatening autoimmune disease. Lupuzor was granted Fast Track status by the Food and Drugs Administration (FDA); it…
Researchers from St. Jude Children’s Research Hospital found that a protein involved in tumor formation suppression also plays a role in preventing autoimmune diseases and other problems through decelerating the immune response. The study was published in the Nature Immunology journal. The research team found that the tumor…
23andMe, Inc., a personal genetics company that helps people better understand and benefit from the human genome, recently announced a new partnership with Pfizer Inc. that will give them access to 23andMe’s research platform, which includes data of the genotypes from more than 800,000 individuals that consented to enroll in the study. From this partnership and…
A national leader in lupus research and chief of Rheumatology at the Beth Israel Deaconess Medical Center (BIDMC) George Tsokos, MD, was recently awarded with two prestigious awards by the Lupus Foundation of America and the American College of Rheumatology (ACR) during the 2014 ACR Annual Scientific Meeting held in Boston.
The Kadmon Corporation’s Phase 2 oral drug, KD025, a potent, bio-available and highly selective inhibitor of ROCK2 (Rho-associated coiled-coiled kinase 2) that can be taken orally was designed as one of its priority candidates to treat lupus through the LRxL-STAT Lupus Drug Repositioning Initiative. The selection of the drug was presented at the annual American College…